N6037
Neridronate
≥97% (NMR), solid, bone resorption inhibitor
Synonym(s):
6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C6H17NO7P2
CAS Number:
Molecular Weight:
277.15
MDL number:
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
Recommended Products
Product Name
Neridronate, ≥97% (NMR), solid
description
may contain <1% (w/w) inorganic salts
Quality Level
Assay
≥97% (NMR)
form
solid
color
white
solubility
H2O: >5 mg/mL
storage temp.
2-8°C
SMILES string
NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O
InChI
1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)
InChI key
PUUSSSIBPPTKTP-UHFFFAOYSA-N
Biochem/physiol Actions
Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Pietro Persiani et al.
Medicine, 96(20), e6766-e6766 (2017-05-18)
The purpose of this study is to compare the results of 2 techniques, tension band wiring (TBW) and fixation with screws, in olecranon fractures in children affected with osteogenesis imperfecta (OI) type I. Between 2010 and 2014, 21 olecranon fractures
Yasmina Hamdous et al.
Journal of nanobiotechnology, 15(1), 74-74 (2017-10-19)
Biologics magnetics nanoparticles, magnetosomes, attract attention because of their magnetic characteristics and potential applications. The aim of the present study was to develop and characterize novel magnetosomes, which were extracted from magnetotactic bacteria, purified to produce apyrogen magnetosome minerals, and
M Benucci et al.
Clinical and experimental rheumatology, 27(4), 567-573 (2009-09-24)
To assess the effects of intramuscular (im) neridronate (NE) on lumbar and femoral neck BMD and on markers of bone turnover in rheumatic patients under chronic low-dose glucocorticoids (GC) therapy. Sixty-nine osteopoenic and osteoporotic patients, affected by rheumatic diseases and
Silvano Adami et al.
Calcified tissue international, 83(5), 301-307 (2008-10-24)
Compliance to osteoporosis treatment with oral bisphosphonates is very poor. Intermittent intravenous bisphosphonate is a useful alternative, but this route is not readily available. Neridronate, a nitrogen-containing bisphosphonate that can be given intramuscularly (IM), was tested in a phase 2
Luigi Gennari et al.
Mini reviews in medicinal chemistry, 9(9), 1052-1063 (2009-08-20)
Paget's disease of bone is a focal skeletal disorder characterized by the formation of structurally abnormal bone, deformity and other complications leading to significant disability and bone pain. Recently, the availability of newer, more potent nitrogen-containing bisphosphonates has improved treatment
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service